Progenics Pharmaceuticals, Inc.  

(Public, NASDAQ:PGNX)   Watch this stock  
Find more results for PGNX
5.08
+0.09 (1.80%)
Real-time:   10:44AM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 4.96 - 5.10
52 week 3.10 - 7.45
Open 5.00
Vol / Avg. 134,278.00/1.61M
Mkt cap 353.44M
P/E     -
Div/yield     -
EPS -0.70
Shares 69.58M
Beta 1.47
Inst. own 75%
Jul 14, 2014
Progenics Pharmaceuticals Inc FDA's Relistor� Appeal Response Conference Call - Webcast
Jun 17, 2014
Progenics Pharmaceuticals Annual Shareholder Meeting
Jun 13, 2014
Progenics Pharmaceuticals Inc Investor Conference Call Following FDA Advisory Committee - Webcast
Jun 5, 2014
Progenics Pharmaceuticals at Jefferies Global Healthcare Conference
May 9, 2014
Q1 2014 Progenics Pharmaceuticals Earnings Release
May 9, 2014
Q1 2014 Progenics Pharmaceuticals Earnings Conference Call
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin -513.11% -541.49%
Operating margin -513.77% -546.68%
EBITD margin - -534.74%
Return on average assets -29.19% -44.61%
Return on average equity -39.98% -58.50%
Employees 69 -
CDP Score - -

Address

777 Old Saw Mill River Road
TARRYTOWN, NY 10591
United States - Map
+1-914-7892800 (Phone)
+1-914-7892817 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Progenics Pharmaceuticals, Inc. (Progenics) is a biopharmaceutical company focuses on research and development for biotechnology product candidates in oncology, virology, supportive care and gastroenterology. It is also engaged in research to identify multiplex phosphoinositide 3-kinase inhibitors for blocking signaling pathways in the growth of aggressive cancers. In gastroenterology, its first commercial product is RELISTOR subcutaneous injection. Its principal product candidate is PSMA ADC, a fully human monoclonal antibody-drug conjugate directed against prostate specific membrane antigen, a protein found at high levels on the surface of prostate cancer cells and also on the neovasculature of a number of other types of solid tumors. In January 2013, the Company acquired Molecular Insight Pharmaceuticals, Inc.

Officers and directors

Peter J. Crowley Independent Chairman of the Board
Age: 55
Bio & Compensation  - Reuters
Mark R. Baker J.D. Chief Executive Officer, Director
Age: 58
Bio & Compensation  - Reuters
Paul J. Maddon M.D., Ph.D. Vice Chairman of the Board
Age: 53
Bio & Compensation  - Reuters
Hagop Youssoufian M.D. Executive Vice President - Research & Development
Bio & Compensation  - Reuters
John W. Babich PhD Senior Vice President
Age: 55
Bio & Compensation  - Reuters
Robert J. Israel M.D. Senior Vice President - Medical Affairs & Clinical Research
Age: 56
Bio & Compensation  - Reuters
Nitya G. Ray Ph.D. Senior Vice President - Manufacturing
Age: 60
Bio & Compensation  - Reuters
Angelo W Lovallo Jr Vice President - Finance, Treasurer
Age: 48
Bio & Compensation  - Reuters
Ann Marie Assumma Vice President - Regulatory Affairs
Age: 57
Bio & Compensation  - Reuters
Vivien Wong Ph.D. Vice President - Product Development
Age: 55
Bio & Compensation  - Reuters